title: Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance.
abstract: Inflammation is an important contributor to lung tumor development and progression. In addition, inflammatory signaling may promote epithelial to mesenchymal transition, development of aggressive metastatic tumor phenotypes, and play a role in resistance to targeted therapies. New insights in inflammatory signaling have led to the evaluation of combination therapies that target these specific pathways. In addition to developing the optimal combination of targeted agents, biomarker-based selection of patients who will likely benefit will be critical to the success of this strategy. Here we focus on the potential contribution of inflammatory mediator-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
authors.affiliation: Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. KKrysan@mednet.ucla.edu
authors.forename: Kostyantyn
authors.initials: K
authors.lastname: Krysan
authors.forename: Jay M
authors.initials: JM
authors.lastname: Lee
authors.forename: Mariam
authors.initials: M
authors.lastname: Dohadwala
authors.forename: Brian K
authors.initials: BK
authors.lastname: Gardner
authors.forename: Karen L
authors.initials: KL
authors.lastname: Reckamp
authors.forename: Edward
authors.initials: E
authors.lastname: Garon
authors.forename: Maie
authors.initials: M
authors.lastname: St John
authors.forename: Sherven
authors.initials: S
authors.lastname: Sharma
authors.forename: Steven M
authors.initials: SM
authors.lastname: Dubinett
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000503:physiopathology; D002471:Cell Transformation, Neoplastic; D051546:Cyclooxygenase 2 / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007249:Inflammation; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D020935:MAP Kinase Signaling System / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D043562:Receptors, G-Protein-Coupled; D051546:Cyclooxygenase 2; D066246:ErbB Receptors; D015232:Dinoprostone